Clinical efficacy of umbilical cord-derived menchymal stem cell treatment of refractory chronic graft-versus-host disease
-
摘要:
目的 探讨脐带来源间充质干细胞(MSC)治疗异基因造血干细胞移植术后难治性慢性移植物抗宿主病(cGVHD)的疗效及安全性。 方法 7例恶性血液病患者接受异基因造血干细胞移植术后出现cGVHD,常规免疫抑制剂治疗无效,在原有免疫抑制剂基础上给予脐带来源MSC治疗,细胞数1×106/kg,每周1次,共4次。观察其疗效、安全性和患者存活情况。 结果 7例患者接受MSC输注后,2例获得完全缓解(CR),3例部分缓解(PR),总有效5例(5/7),2例无效(NR)。未发现输注相关不良反应,无患者出现原发病复发。1例患者部分缓解后继发巨细胞病毒肺炎,死于重症肺炎,其余病例均存活。 结论 脐带MSC对于治疗难治性cGVHD具有一定的疗效,且输注过程安全。 Abstract:Objective To evaluate the clinical efficacy and safety of umbilical cord-derived mesenchymal stem cell (MSC) treatment of refractory chronic graft-versus-host disease (cGVHD) after allogene hematopoietic stem cell transplantation. Methods Seven patients developed with cGVHD following allogene hematopoietic stem cell transplantation. Conventional immunosuppressive agent treatment yielded no efficacy. Based upon immunosuppressive agent therapy, umbilical cord-derived MSC treatment was supplemented with a cell density of 1×106/kg, once a week for consecutive 4 times. Clinical efficacy, safety and survival of the patients were observed. Results Among 7 patients receiving MSC injection, 2 obtained complete response (CR) and 3 had partial response (PR) with an overall response rate of 5/7, and the remaining 2 cases achieved no response (NR). No adverse reactions were induced by MSC injection. No patient had primary disease recurrence. One patient developed secondary cytomegalovirus pneumonia after PR and died from severe pneumonia. The remaining patients survived. Conclusions Umbilical cord -derived MSC injection is an efficacious and safe therapy of cGVHD. -
表 1 脐带MSC治疗后疗效评价
Table 1. Efficacy evaluation of human umbilical cord MSC therapy
病例 性别 年龄(岁) 诊断 受累器官 合用药物 MSC输注次数 疗效 1 男 44 急性淋巴细胞白血病 肝脏、口腔 西罗莫司、甲泼尼龙 4 CR 2 男 31 急性髓细胞白血病 皮肤、口腔 西罗莫司、甲泼尼龙 4 CR 3 女 38 急性髓细胞白血病 皮肤 甲泼尼龙 4 PR 4 男 42 急性淋巴细胞白血病 眼、口腔、皮肤 甲泼尼龙 4 PR 5 女 43 非霍奇金淋巴瘤 肝脏 他克莫司、甲泼尼龙 4 PR 6 男 32 急性混合细胞白血病 肺、肾 甲泼尼龙 3 NR 7 女 27 急性髓细胞白血病 皮肤 泼尼松 4 NR -
[1] Arai S, Arora M, Wang T, et al. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research[J]. Biol Blood Marrow Transplant, 2015, 21(2): 266-274. doi: 10.1016/j.bbmt.2014.10.021 [2] Herrmann R, Sturm M, Shaw K, et al. Mesenchymal stromal cell therapy for steroid-refractory acute and chronic graft versus host disease: a phase 1 study[J]. Int J Hematol, 2012, 95(2):182-188. doi: 10.1007/s12185-011-0989-2 [3] Gao F, Chiu SM, Motan DA, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects[J]. Cell Death Dis, 2016,7: e2062. doi: 10.1038/cddis.2015.327 [4] Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft-versus-host disease. national institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: Ⅳ. the 2014 Response Criteria Working Group report[J]. Biol Blood Marrow Transplant, 2015, 21(6): 984-999. doi: 10.1016/j.bbmt.2015.02.025 [5] Le Blanc K, Rasmusson I, Sunberg B, et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells[J]. Lancet, 2004, 363 (9419): 1439-1441. doi: 10.1016/S0140-6736(04)16104-7 [6] Liu JJ, Li D, Ju X, et al. Umbilical cord-derived mesenchymal stem cells retain immunomodulatory and anti-oxidative activities after neural induction[J]. Neural Regen Res, 2012, 7(34): 2663-2672. http://cn.bing.com/academic/profile?id=1510063224&encoded=0&v=paper_preview&mkt=zh-cn [7] Zhou J, Tian G, Wang J, et al. Neural cell injury microenvironment induces neural differentiation of human umbilical cord mesenchymal stem cells[J]. Neural Regen Res, 2012, 7(34): 2689-2697. [8] 孙燕玲,李旭东,林东军,等. 非血缘脐血移植治疗高危急性白血病的临床研究[J]. 器官移植, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.htmlYL, Li XD, Lin DJ, et al. Clinical study on treatment of high-risk acute leukemia with unrelated cord blood transplantation[J]. Organ Transplant, 2015, 6(6): 420-424. http://www.organtranspl.com/browse/detail/qkid/89/id/150.html [9] Gao L, Zhang Y, Hu B, et al. Phase Ⅱ multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation[J]. J Clin Oncol, 2016, 34 (24): 2834-2850. http://cn.bing.com/academic/profile?id=2460851798&encoded=0&v=paper_preview&mkt=zh-cn [10] Introna M, Lucchini G, Dander E, et al. Treatment of graft versus host disease with mesenchymal stromal cells: a phase Ⅰ study on 40 adult and pediatric patients[J]. Biol Blood Marrow Transplant, 2014, 20(3) 375-381. doi: 10.1016/j.bbmt.2013.11.033 [11] 黄英丹,肖翠容,林进宗,等. 脐带来源间充质干细胞治疗异基因造血干细胞移植后慢性移植物抗宿主病[J]. 中国组织工程研究,2014, 18(50): 8093-8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htmHuang YD, Xiao CR, Lin JZ, et al. Treatment of chronic graft-versus-host disease with human umbilical cord mesenchymal stem cells[J]. Chin J Tissue Eng Res, 2014,18 (50): 8093- 8097. http://www.cnki.com.cn/Article/CJFDTOTAL-XDKF201450012.htm [12] 卢荣标,陆春. 移植物抗宿主疾病皮肤损害的治疗进展[J]. 器官移植, 2013 , 4 (3) : 169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htmLu RB, Lu C. Therapeutic advance in cutaneous graft-versus-host disease[J]. Organ Transplant,2013,4(3):169-176. http://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ201303012.htm [13] Weng JY, Du X, Geng SX, et al. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD[J]. Bone Marrow Trasplant, 2010, 45(12): 1732-1740. doi: 10.1038/bmt.2010.195 [14] Lazarus HM, Pavletic SZ. Umbilical cord blood-derived mesenchymal stromal cells for reducing chronic graft-versus-host disease after haploidentical transplantation: just another labor-intensive strategy, or showing the way?[J]. J Clin Oncol, 2016, 34 (24): 2812-2813. doi: 10.1200/JCO.2016.67.7344 [15] Kim N, Im KI, Lim JY, et al. Mesenchymal stem cells for the treatment and prevention of graft-versus-host disease: experiments and practice[J]. Ann Hematol, 2013, 92(10): 1295-1308. doi: 10.1007/s00277-013-1796-z [16] Kuzmina LA, Petinati NA, Parovichnikova EN, et al. Multipotent mesenchymal stromal cells for the prophylaxis of acute graft-versus-host disease-a phase Ⅱ study[J]. Stem Cells Int, 2012: 968213. http://cn.bing.com/academic/profile?id=2126957024&encoded=0&v=paper_preview&mkt=zh-cn [17] Liu K, Chen Y, Zeng Y, et al. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: a randomized, controlled clinical study[J]. Stem Cells Dev, 2011, 20(10): 1679-1685. doi: 10.1089/scd.2010.0447 [18] Zhao K, Lou R, Huang F, et al. Immunomodulation effects of mesenchymal stromal cells on acute graft-versus-host disease after hematopoietic stem cell transplantation[J]. Biol Blood Marrow Transplant, 2015, 21(1): 97-104. doi: 10.1016/j.bbmt.2014.09.030